{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:14:34Z","timestamp":1722888874115},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00277-016-2614-1","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T02:12:19Z","timestamp":1456107139000},"page":"719-732","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method"],"prefix":"10.1007","volume":"95","author":[{"name":"on behalf of GEMFIN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Besses","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"P\u00e9rez Encinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Raya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jim\u00e9nez Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mart\u00ednez Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Burgaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"issue":"1","key":"2614_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14\u201322","journal-title":"Leukemia"},{"issue":"7","key":"2614_CR2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi AM, Barbui T (2014) An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 28(7):1407\u20131413","journal-title":"Leukemia"},{"key":"2614_CR3","doi-asserted-by":"crossref","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kr\u00f6ger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 29(6):761\u2013770","DOI":"10.1200\/JCO.2010.31.8436"},{"issue":"2","key":"2614_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.leukres.2013.09.008","volume":"38","author":"G Barosi","year":"2014","unstructured":"Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi F, Saglio A, Barbui T, Tura S (2014) Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res 38(2):155\u2013160","journal-title":"Leuk Res"},{"issue":"25","key":"2614_CR5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"25","key":"2614_CR6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405","journal-title":"N Engl J Med"},{"issue":"10","key":"2614_CR7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant\u2019Antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544\u20131551","journal-title":"Blood"},{"issue":"10","key":"2614_CR8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123(10):1552\u20131555","journal-title":"Blood"},{"issue":"8","key":"2614_CR9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larran","year":"2010","unstructured":"Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, Ayats R, Salvador C, Munta\u00f1ola A, Bellosillo B, Vicente V, Hernandez-Nieto L, Burgaleta C, Xicoy B, Besses C (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116(8):1205\u20131210","journal-title":"Blood"},{"issue":"6","key":"2614_CR10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12321","volume":"161","author":"A Alvarez-Larran","year":"2013","unstructured":"Alvarez-Larran A, Pereira A, Arellano-Rodrigo E, Hernandez-Boluda JC, Cervantes F, Besses C (2013) Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol 161(6):865\u2013871","journal-title":"Br J Haematol"},{"issue":"6","key":"2614_CR11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","volume":"122","author":"A Quintas-Cardama","year":"2013","unstructured":"Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122(6):893\u2013901","journal-title":"Blood"},{"issue":"10","key":"2614_CR12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE, ANAHYDRET Study Group (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121(10):1720\u20131728","journal-title":"Blood"},{"issue":"26","key":"2614_CR13","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133","journal-title":"Blood"},{"issue":"6","key":"2614_CR14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, M\u00fcllauer L, Rodeghiero F, d\u2019Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A (2012) A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 120(6):1197\u20131201","journal-title":"Blood"},{"issue":"10","key":"2614_CR15","first-page":"1","volume":"12","author":"C-C Hsu","year":"2007","unstructured":"Hsu C-C, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res Eval 12(10):1\u20138","journal-title":"Pract Assess Res Eval"},{"issue":"2","key":"2614_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2648.2006.03716.x","volume":"53","author":"S Keeney","year":"2006","unstructured":"Keeney S, Hasson F, McKenna H (2006) Consulting the oracle: ten lessons from using the Delphi technique in nursing research. J Adv Nurs 53(2):205\u2013212","journal-title":"J Adv Nurs"},{"issue":"4","key":"2614_CR17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V99.4.1144","volume":"99","author":"MB Streiff","year":"2002","unstructured":"Streiff MB, Smith B, Spivak JL (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members\u2019 practice patterns. Blood 99(4):1144\u20131149","journal-title":"Blood"},{"issue":"2","key":"2614_CR18","first-page":"215","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzuconi MG, Rodeghiero F, Tura S (2004) Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89(2):215\u2013232","journal-title":"Haematologica"},{"issue":"7","key":"2614_CR19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jclinpath-2014-202246","volume":"67","author":"JM Raya","year":"2014","unstructured":"Raya JM, Montes-Moreno S, Acevedo A, Ferrandez A, Fraga M, Garcia JF, Garcia M, Mayordomo-Aranda E, Menarquez J, Besses C, Calzada R, Rozman M (2014) Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardized diagnostic report. J Clin Pathol 67(7):620\u2013625","journal-title":"J Clin Pathol"},{"issue":"23","key":"2614_CR20","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d\u2019Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, M\u00fcllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179\u20133184","journal-title":"J Clin Oncol"},{"key":"2614_CR21","author":"A Alvarez-Larran","year":"2015","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, Martinez-Lopez J, Cuevas B, Mata MI, Garcia-Gutierrez V, Arag\u00fces P, Montesdeoca S, Burgaleta C, Caballero G, Hernandez-Rivas JA, Duran MA, Gomez-Casares MT, Besses C (2015) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. doi: 10.1111\/bjh.13886","journal-title":"Br J Haematol"},{"issue":"6","key":"2614_CR22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2013.380","volume":"28","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A (2014) Rethinking the diagnostic criteria of polycythemia vera. Leukemia 28(6):1191\u20131195","journal-title":"Leukemia"},{"issue":"3","key":"2614_CR23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","volume":"149","author":"CN Harrison","year":"2010","unstructured":"Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, van der Walt J, Wilkins B, McMullin MF, British Committee for Standards in Haematology (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149(3):352\u2013375","journal-title":"Br J Haematol"},{"issue":"20","key":"2614_CR24","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829\u20134833","journal-title":"Blood"},{"issue":"23","key":"2614_CR25","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778\u20134781","journal-title":"Blood"},{"issue":"8","key":"2614_CR26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","volume":"90","author":"F Palandri","year":"2011","unstructured":"Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N (2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 90(8):933\u2013938","journal-title":"Ann Hematol"},{"issue":"9","key":"2614_CR27","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","volume":"7","author":"F Passamonti","year":"2009","unstructured":"Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M (2009) Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 7(9):1587\u20131589","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2614_CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","volume":"120","author":"PJ Campbell","year":"2012","unstructured":"Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, Forsyth C, Harrison CN, Green AR (2012) Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 120(7):1409\u20131411","journal-title":"Blood"},{"issue":"22","key":"2614_CR29","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857\u20135859","journal-title":"Blood"},{"key":"2614_CR30","unstructured":"European Medicines Agency (2014) Xagrid summary of product characteristics (Internet). Shire Pharmaceuticals Ltd. (updated 2014). Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000480\/WC500056557.pdf Accessed 27 July 2015"},{"issue":"18","key":"2614_CR31","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706\u20134715","journal-title":"Blood"},{"key":"2614_CR32","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01259856?term=essential+thrombocythemia&rank=4 . Accessed 27 July 2015"},{"issue":"12","key":"2614_CR33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","volume":"93","author":"A Alvarez-Larran","year":"2014","unstructured":"Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, Ferrer-Marin F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martinez-Trillos A, Gomez-Casares MT, Duran MA, Marcote B, Ancochea A, Senin A, Angona A, Gomez M, Vicente V, Cervantes F, Bellosillo B, Besses C (2014) Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 93(12):2037\u20132043","journal-title":"Ann Hematol"},{"issue":"16","key":"2614_CR34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507\u20132513","journal-title":"Blood"},{"issue":"3","key":"2614_CR35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","volume":"118","author":"F Cervantes","year":"2002","unstructured":"Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118(3):786\u2013790","journal-title":"Br J Haematol"},{"issue":"3","key":"2614_CR36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 110(3):577\u2013583","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2614-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2614-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2614-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:04Z","timestamp":1559037004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2614-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2614"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2614-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}